OOIR: Observatory of International Research

Papers

(The H4-Index of Clinical Pharmacology & Therapeutics is 38. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)

Article	Citations
Sodium Bicarbonate Prescription and Extracellular Volume Increase: Real‐world Data Results from the AlcalUN Study	308
Return to SENDer: The Submitted Electronic Data for Nonclinical Cardiovascular Studies is Not Facilitating Transparency, Translation or Innovation	240
Issue Information	205
Predicting Survival in Patients with Advanced NSCLC Treated with Atezolizumab Using Pre‐ and on‐Treatment Prognostic Biomarkers	203
In This Issue	128
ASCPT News	118
In This Issue	110
In this Issue	108
Correction to: Pharmacokinetics, Pharmacodynamics, and Safety of Vadadustat in Healthy Volunteers and Patients with Chronic Kidney Disease	103
	102
Liquid Biopsies or Therapeutic Drug Monitoring for CYP Activity Profile Determination	89
French‐Speaking Network of Pharmacogenetics (RNPGx) Recommendations for Clinical Use of Mavacamten	89
ICH S7B In Vitro Assays Do Not Address Mechanisms of QT_C Prolongation for Peptides and Proteins – Data in Support of Not Needing Dedicated QT_C Studies	73
A Randomized Trial Comparing Standard of Care to Bayesian Warfarin Dose Individualization	73
Model‐Based Prediction of Irinotecan‐Induced Grade 4 Neutropenia in Advanced Cancer Patients: Influence of Demographic and Clinical Factors	71
Factors Influencing Medication Adherence in Heart Failure Patients—A Survey Among Cardiac Healthcare Providers	62
The Efficacy, Effectiveness, and Efficiency of Integrated QTc Assessment: Rationalizing Approaches to New Drug Modalities	62
Model‐Informed Selection of the Recommended Phase 2 Dosage for Anti‐TIGIT Immunotherapy Leveraging co‐Expressed PD‐1 Inhibitor Target Engagement	60
Integrated Evidence Planning for Enhancing Patient Care: Harnessing the Power of Real‐World Evidence	56
Chinese Expert Consensus on the Clinical Diagnosis and Management of Statin Intolerance	55
Pharmacogenomic Prescribing Guidelines: Are They Always Useful?	55
Progress in Clinical Pharmacology in China: A Randomized Controlled Study to Advance Genotype‐Guided Precision Medicine	50
Protecting the Kidney: The Unexpected Logic of Inhibiting a Glucose Transporter	49
Effect of CYP3A5 and CYP3A4 Genetic Variants on Fentanyl Pharmacokinetics in a Pediatric Population	48
More Than Pharmacokinetics: Transporters in Clinical Pharmacology	47

Estimating Culprit Drugs for Adverse Drug Reactions Based on Bayesian Inference	46
Reply to “Interpretation of Pharmacovigilance Disproportionality Analyses”	46
DrugWAS: Drug‐wide Association Studies for COVID‐19 Drug Repurposing	45
Reply to “Questioning Bayesian Inference‐Based Models for Estimating Culprit Drugs for Adverse Drug Reactions”	45
A Guide for Implementing DPYD Genotyping for Systemic Fluoropyrimidines into Clinical Practice	42
Neurodegenerative Diseases: The Value of Early Predictive End Points	42
Infection Risk Associated with High‐Efficacy Disease‐Modifying Agents in Multiple Sclerosis: A Retrospective Cohort Study	42
Enhancing External Control Arm Analyses through Data Calibration and Hybrid Designs	41
How to Successfully Generate an Alternative Approach to a Thorough QT Study: GLPG1972 as an Example	39
Longitudinal Model‐Based Meta‐Analysis of Lung Function Response to Support Phase III Study Design in Chinese Patients With Asthma	39
The Broader Context of Liquid Biopsy in Absorption, Distribution, Metabolism, and Elimination	39
Development of a Multifaceted Program for Pharmacogenetics Adoption at an Academic Medical Center: Practical Considerations and Lessons Learned	38
Using Machine Learning to Determine a Suitable Patient Population for Anakinra for the Treatment of COVID‐19 Under the Emergency Use Authorization	38
A Biological Basis for Pharmacokinetics: The Remote Sensing and Signaling Theory	38